1. bookVolumen 57 (2019): Edición 4 (December 2019)
Detalles de la revista
Primera edición
30 Mar 2015
Calendario de la edición
4 veces al año
Acceso abierto

Idiopathic thrombocytopenic purpura (ITP) – new era for an old disease

Publicado en línea: 16 Dec 2019
Volumen & Edición: Volumen 57 (2019) - Edición 4 (December 2019)
Páginas: 273 - 283
Recibido: 20 Feb 2018
Detalles de la revista
Primera edición
30 Mar 2015
Calendario de la edición
4 veces al año

1. ONISÂI M, VLĂDĂREANU AM, DELCEA C, CIORĂSCU M, BUMBEA H, NICOLESCU A, et al. Perinatal outcome for pregnancies complicated with thrombocytopenia. J Matern Fetal Neonatal Med. 2012; 25(9):1622–6.10.3109/14767058.2011.64824522220678Search in Google Scholar

2. CORTELAZZO S1, FINAZZI G, BUELLI M, MOLTENI A, VIERO P, BARBUI T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991; 77(1):31–3.10.1182/blood.V77.1.31.31Search in Google Scholar

3. KISTANGURI G, MCCRAE K. Immune Thrombocytopenia. Hematol Oncol Clin North Am. 2013; 27(3):495–520.10.1016/j.hoc.2013.03.001367285823714309Search in Google Scholar

4. STASI R, NEWLAND AC. ITP: a historical perspective. Br J Haematol. 2011; 153(4):437–450.10.1111/j.1365-2141.2010.08562.x21466538Search in Google Scholar

5. COOPER N. State of the art – how I manage immune thrombocytopenia. Br J Haematol. 2017 Apr; 177(1):39–54.10.1111/bjh.1451528295192Search in Google Scholar

6. CINES DB, BUSSEL JB, LIEBMAN HA, LUNING PRAK ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009; 113:6511–21.10.1182/blood-2009-01-129155271091319395674Search in Google Scholar

7. CINES DB, LIEBMAN H, STASI R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009; 46:S2–14.10.1053/j.seminhematol.2008.12.005268243819245930Search in Google Scholar

8. CUKER A, CINES DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2010; 2010:377–84.10.1182/asheducation.V2010.1.377.3643150Search in Google Scholar

9. TOLTL LJ, NAZI I, JAFARI R, ARNOLD DM. Piecing together the humoral and cellular mechanisms of immune thrombocytopenia. Semin Thromb Hemost. 2011; 37(6):631–639.10.1055/s-0031-1291373393845522102266Search in Google Scholar

10. SEMPLE JW, PROVAN D, GARVEY MB, FREEDMAN J. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol. 2010; 17(6):590–595.10.1097/MOH.0b013e32833eaef320739879Search in Google Scholar

11. MCMILLAN R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009; 23(6):1163–1175.10.1016/j.hoc.2009.08.008Search in Google Scholar

12. NUGENT D, MCMILLAN R, NICHOL JL, SLICHTER SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009; 146(6):585–596.10.1111/j.1365-2141.2009.07717.xSearch in Google Scholar

13. STASI R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost. 2012; 38(5):454–462.10.1055/s-0032-1305780Search in Google Scholar

14. BLANCHETTE V, BOLTON-MAGGS P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am. 2010; 24(1):249–273.10.1016/j.hoc.2009.11.004Search in Google Scholar

15. BREAKEY VR, BLANCHETTE VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. Semin Thromb Hemost. 2011; 37(7):745–755.10.1055/s-0031-1297165Search in Google Scholar

16. LIEBMAN HA. Viral-associated immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2008:212–218.10.1182/asheducation-2008.1.212Search in Google Scholar

17. RAJAN SK, ESPINA BM, LIEBMAN HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005; 129(6):818–824.10.1111/j.1365-2141.2005.05542.xSearch in Google Scholar

18. ZHANG W, NARDI MA, BORKOWSKY W, LI Z, KARPATKIN S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood. 2009; 113(17):4086–4093.10.1182/blood-2008-09-181073Search in Google Scholar

19. LI Z, NARDI MA, KARPATKIN S. Role of molecular mimicry to HIV-1 peptides in HIV-1 related immunologic thrombocytopenia. Blood. 2005; 106:572–576.10.1182/blood-2005-01-0243Search in Google Scholar

20. NARDI M, TOMLINSON S, GRECO MA, KARPATKIN S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell. 2001; 106:551–561.10.1016/S0092-8674(01)00477-9Search in Google Scholar

21. LIEBMAN HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol. 2009; 46(1 Suppl 2):S33–S36.10.1053/j.seminhematol.2008.12.00419245932Search in Google Scholar

22. TEACHEY DT. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr. 2012; 24(1):1–8.10.1097/MOP.0b013e32834ea739367376322157362Search in Google Scholar

23. MICHEL M, CHANET V, DECHARTRES A, MORIN AS, PIETTE JC, CIRASINO L, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009; 114(15):3167–3172.10.1182/blood-2009-04-21536819638626Search in Google Scholar

24. ARNAL C, PIETTE JC, LEONE J, TAILLAN B, HACHULLA E, ROUDOT-THORAVAL F, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002; 29(1):75–83.Search in Google Scholar

25. PANITSAS FP, THEODOROPOULOU M, KOURAKLIS A, KARAKANTZA M, THEODOROU GL, ZOUMBOS NC, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004; 103(7):2645–2647.10.1182/blood-2003-07-226814670926Search in Google Scholar

26. SAKAKURA M, WADA H, TAWARA I, NOBORI T, SUGIYAMA T, SAGAWA N, et al. Reduced CD4+CD25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007; 120(2):187–193.10.1016/j.thromres.2006.09.00817067661Search in Google Scholar

27. RODEGHIERO F, STASI R, GERNSHEIMER T, MICHEL M, PROVAN D, ARNOLD D, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113(11):2386–93.10.1182/blood-2008-07-16250319005182Search in Google Scholar

28. BAO W, BUSSEL JB, HECK S, HE W, KARPOFF M, BOULAD N, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010; 116(22):4639–4645.10.1182/blood-2010-04-281717299611920688957Search in Google Scholar

29. STASI R, COOPER N, DEL POETA G, STIPA E, LAURA EVANGELISTA M, ABRUZZESE E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008; 112(4):1147–1150.10.1182/blood-2007-12-12926218375792Search in Google Scholar

30. ROARK JH, BUSSEL JB, CINES DB, SIEGEL DL. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood. 2002; 100:1388–1398.10.1182/blood.V100.4.1388.h81602001388_1388_1398Search in Google Scholar

31. OLSSON B, ANDERSSON PO, JERNAS M, JACOBSSON S, CARLSSON B, CARLSSON LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003; 9(9):1123–1124.10.1038/nm92112937414Search in Google Scholar

32. OLSSON B, RIDELL B, CARLSSON L, JACOBSSON S, WADENVIK H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood. 2008; 112(4):1078–1084.10.1182/blood-2008-02-13940218519809Search in Google Scholar

33. MCMILLAN R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: Assays and epitopes. J Pediatr Hematol Oncol. 2003; 25:S57–S61.10.1097/00043426-200312001-0001314668642Search in Google Scholar

34. CINES DB, BLANCHETTE VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346:13–995.Search in Google Scholar

35. NAJAOUI A, BAKCHOUL T, STOY J, BEIN G, RUMMEL MJ, SANTOSO S, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012; 88(2):167–174.10.1111/j.1600-0609.2011.01718.x21985182Search in Google Scholar

36. NEYLON AJ, SAUNDERS PW, HOWARD MR, PROCTOR SJ, TAYLOR PR. On behalf of the Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Brit J Haematol. 2003; 122:966–974.10.1046/j.1365-2141.2003.04547.x12956768Search in Google Scholar

37. PSAILA B, PETROVIC A, PAGE LK, MENELL J, SCHONHOLZ M, BUSSEL JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood. 2009; 114(23):4777–4783.10.1182/blood-2009-04-215525278628819767509Search in Google Scholar

38. KUHNE T, BERCHTOLD W, MICHAELS LA, WU R, DONATO H, ESPINA B, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011; 96(12):1831–1837.10.3324/haematol.2011.050799323226621880634Search in Google Scholar

39. NORGAARD M, JENSEN AO, ENGEBJERG MC, FARKAS DK, THOMSEN RW, CHA S, et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood. 2011; 117(13): 3514–3520.10.1182/blood-2010-10-31281921263148Search in Google Scholar

40. MITTAL S, BLAYLOCK MG, CULLIGAN DJ, BARKER RN, VICKERS MA. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica. 2008; 93(1):151–152.10.3324/haematol.1182218166805Search in Google Scholar

41. NEWTON JL, REESE JA, WATSON SI, VESELY SK, BOLTON-MAGGS PH, GEORGE JN, ET AL. Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2011; 86(5):420–429.10.1111/j.1600-0609.2011.01587.x21323737Search in Google Scholar

42. KUTER DJ, MATHIAS SD, RUMMEL M, MANDANAS R, GIAGOUNIDIS AA, WANG X, et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol. 2012; 87(5):558–561.10.1002/ajh.2316322460421Search in Google Scholar

43. MATHIAS SD, BUSSEL JB, GEORGE JN, MCMILLAN R, OKANO GJ, NICHOL JL. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes. 2007; 5:11.10.1186/1477-7525-5-11180805217316442Search in Google Scholar

44. ALEDORT LM, HAYWARD CP, CHEN MG, NICHOL JL, BUSSEL J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004; 76(3):205–213.10.1002/ajh.2010415224353Search in Google Scholar

45. DIZ-KUCUKKAYA R, HACEHANEFIOGLU A, YENEREL M, TURGUT M, KESKIN H, NALÇACI M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001; 98:1760–1764.10.1182/blood.V98.6.1760Search in Google Scholar

46. NEUNERT C, LIM W, CROWTHER M, COHEN A, SOLBERG L, JR, CROWTHER MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16):4190–4207.10.1182/blood-2010-08-30298421325604Search in Google Scholar

47. PROVAN D, STASI R, NEWLAND AC, BLANCHETTE VS, BOLTON-MAGGS P, BUSSEL JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115:168–186.10.1182/blood-2009-06-22556519846889Search in Google Scholar

48. PEERSCHKE EI, YIN W, GHEBREHIWET B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010; 47(13):2170–2175.10.1016/j.molimm.2010.05.009290432620621693Search in Google Scholar

49. NORIS P, KLERSY C, ZECCA M, ARCAINI L, PECCI A, MELAZZINI F, et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost. 2009; 7(12):2131–2136.10.1111/j.1538-7836.2009.03614.x19740094Search in Google Scholar

50. BARSAM SJ, PSAILA B, FORESTIER M, PAGE LK, SLOANE PA, GEYER JT, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 2011; 117(21):5723–5732.10.1182/blood-2010-11-321398311002921389318Search in Google Scholar

51. HOUWERZIJL EJ, BLOM NR, VAN DER WANT JJ, ESSELINK MT, KOORNSTRA JJ, SMIT JW, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004; 103(2):500–506.10.1182/blood-2003-01-027512969975Search in Google Scholar

52. MCMILLAN R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009; 23(6):1163–1175.10.1016/j.hoc.2009.08.00819932426Search in Google Scholar

53. NURDEN AT, FRESON K, SELIGSOHN U. Inherited platelet disorders Haemophilia. 2012; 18(Suppl 4):154–60.10.1111/j.1365-2516.2012.02856.x22726100Search in Google Scholar

54. BALDUINI CL, PECCI A, SAVOIA A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol. 2011; 154(2):161–174.10.1111/j.1365-2141.2011.08716.x21542825Search in Google Scholar

55. BERNDT MC, ANDREWS RK. Bernard-Soulier syndrome. Haematologica. 2011; 96(3):355–359.10.3324/haematol.2010.039883304626521357716Search in Google Scholar

56. PORTEILJE JEA, WESTENDORP RGJ, KLUIN-NELEMANS HC, BRAND A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001; 97:2549–2554.10.1182/blood.V97.9.254911313240Search in Google Scholar

57. MAZZUCCONI MG, FAZI P, BERNASCONI S, DE ROSSI G, LEONE G, GUGLIOTTA L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007; 109:1401–1407.10.1182/blood-2005-12-01522217077333Search in Google Scholar

58. CHENG Y, WONG RS, SOO YO, CHUI CH, LAU FY, CHAN NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003; 349:831–836.10.1056/NEJMoa03025412944568Search in Google Scholar

59. ZAJA F, BACCARANI M, MAZZA P, BOCCHIA M, GUGLIOTTA L, ZACCARIA A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010; 115(14):2755–2762.10.1182/blood-2009-07-22981520130241Search in Google Scholar

60. BAE SH, RYOO H, LEE WS. High dose dexamethasone vs conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial. Blood. 2010; 116.10.1182/blood.V116.21.3687.3687Search in Google Scholar

61. LEONTYEV D, KATSMAN Y, BRANCH DR. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcgamma receptor for the amelioration of experimental ITP. Blood. 2012; 119(22):5261–5264.10.1182/blood-2012-03-41569522508937Search in Google Scholar

62. COOPER N. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am. 2009; 23(6):1317–1327.10.1016/j.hoc.2009.09.00219932436Search in Google Scholar

63. GAINES AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106(5):1532–1537.10.1182/blood-2004-11-4303Search in Google Scholar

64. COOPER N, WOLOWSKI BMR, FODERO EM, NOVOA M, LEBER M, BEER JH, et al. Does treatment with intermittent infusion of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy. Blood. 2002; 99:1922–1927.10.1182/blood.V99.6.1922Search in Google Scholar

65. GEORGE JN, KOJOURI K, PERDUE JJ, VESELY SK. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Sem Hematol. 2000; 37:290–298.10.1016/S0037-1963(00)90107-0Search in Google Scholar

66. PSAILA B, BUSSEL JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol. 2008; 143(1):16–26.10.1111/j.1365-2141.2008.07275.x18573111Search in Google Scholar

67. PATEL VL, MAHEVAS M, LEE SY, STASI R, CUNNINGHAM-RUNDLES S, GODEAU B, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012; 119(25):5989–5995.10.1182/blood-2011-11-393975338301422566601Search in Google Scholar

68. PROVAN D, BUTLER T, EVANGELISTA ML, AMADORI S, NEWLAND AC, STASI R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007; 92(12):1695–1698.10.3324/haematol.1170918055995Search in Google Scholar

69. STASI R, DEL POETA G, EVANGELISTA ML, COOPER N, AMADORI S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110:2924–2930.10.1182/blood-2007-02-06899917548576Search in Google Scholar

70. RODEGHIERO F. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. Eur J Haematol Suppl. 2008; 69:19–26.10.1111/j.1600-0609.2007.01000.x18211569Search in Google Scholar

71. MIKHAEL J, NORTHRIDGE K, LINDQUIST K, KESSLER C, DEUSON R, DANESE M. Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review. Am J Hematol. 2009; 84(11):743–748.10.1002/ajh.2150119714591Search in Google Scholar

72. THOMSEN RW, SCHOONEN WM, FARKAS DK, RIIS A, JACOBSEN J, FRYZEK JP, et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med. 2009;151(8): 546–555.10.7326/0003-4819-151-8-200910200-0000819841456Search in Google Scholar

73. GHANIMA W, GODEAU B, CINES DB, BUSSEL JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012; 120(5):960–969.10.1182/blood-2011-12-309153Search in Google Scholar

74. KUTER DJ, RUMMEL M, BOCCIA R, MACIK BG, PABINGER I, SELLESLAG D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010; 363(20):1889–1899.10.1056/NEJMoa1002625Search in Google Scholar

75. STASI R, BOSWORTH J, RHODES E, SHANNON MS, WILLIS F, GORDON-SMITH EC. Thrombopoietic agents. Blood Rev. 2010; 24(4–5):179–190.10.1016/j.blre.2010.04.002Search in Google Scholar

76. KUTER DJ. Romiplostim. Cancer Treat Res. 2011; 157:267–288.10.1007/978-1-4419-7073-2_16Search in Google Scholar

77. KUTER DJ, BUSSEL JB, LYONS RM, PULLARKAT V, GERNSHEIMER TB, SENECAL FM, ET AL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371(9610): 395–403.10.1016/S0140-6736(08)60203-2Search in Google Scholar

78. BUSSEL JB, PINHEIRO MP. Eltrombopag. Cancer Treat Res. 2011; 157:289–303.Search in Google Scholar

79. CHENG G, SALEH MN, MARCHER C, VASEY S, MAYER B, AIVADO M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763):393–402.10.1016/S0140-6736(10)60959-2Search in Google Scholar

80. SALEH MN, CHENG G, BUSSEL JB, MEYER O, BAILEY CK, ARNING M, et al. Safety and efficacy of extended treatment with Eltrombopag in adults with chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013; 121(3):537–4510.1182/blood-2012-04-42551223169778Search in Google Scholar

81. CUKER A, CHIANG EY, CINES DB. Safety of the Thrombopoiesis-stimulating Agents for the Treatment of Immune Thrombocytopenia. Curr Drug Saf. 2010; 5(2):171–181.10.2174/15748861079093619619534637Search in Google Scholar

82. IMBACH P, CROWTHER M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011; 365(8):734–741.10.1056/NEJMct101420221864167Search in Google Scholar

83. SARPATWARI A, BENNETT D, LOGIE JW, SHUKLA A, BEACH KJ, NEWLAND AC, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010; 95:1167–117510.3324/haematol.2009.018390289504220145266Search in Google Scholar

84. JANSSENS A, TARANTINO MD, BIRD R. Final results from a multicenter, international, single arm study evaluating the efficacy and safety of Romiplostim in adults with primary immune thrombocytopenia. Blood 2011; 118.10.1182/blood.V118.21.3279.3279Search in Google Scholar

85. BRYNES RK, ORAZI A, VERMA S, BRAINSKY K, BAILEY CK, BAKSHI K. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with Eltrombopag-data from the EXTEND study. Blood. 2011; 118.10.1182/blood.V118.21.528.528Search in Google Scholar

86. SPAHR JE, RODGERS GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008; 83(2):122–125.10.1002/ajh.2106017874448Search in Google Scholar

87. KOJOURI K, VESELY SK, TERRELL D, GEORGE J. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104:2623–2634.10.1182/blood-2004-03-116815217831Search in Google Scholar

88. VESELY SK, ERDUE JJ, RIZVI MA, TERRELL D, GEORGE JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. Ann Intern Med 2004; 140:112–120.10.7326/0003-4819-140-3-200402030-0001214734334Search in Google Scholar

89. KÜHNE T, BLANCHETTE V, BUCHANAN GR, RAMENGHI U, DONATO H, TAMMINGA RY, et al. Splenectomy in children with idiopathic thrombocytopenic purpura: a prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 2007; 49:829–834.10.1002/pbc.2110817171689Search in Google Scholar

90. ARNOLD DM, KELTON JG. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007; 44:S12–S23.10.1053/j.seminhematol.2007.11.00318096468Search in Google Scholar

91. GODEAU B, PROVAN D, BUSSEL J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007; 14:535–556.10.1097/MOH.0b013e3282b9748f17934364Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo